Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeldesivir in Nonhospitalized Adults With Acute RSV Infection
NCT06585150Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Obeldesivir with Placebo (2 arms). Primary endpoints: Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ), Percentage of Participants Who Experienced Treatment-emergent Adverse Events up to 35 days and 3 more. Started Oct 2024; status: terminated.
02
Drugs
obeldesivir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06585150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585150.